IRIS
BARGAGLI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.776
EU - Europa 24.316
AS - Asia 13.473
SA - Sud America 2.476
AF - Africa 748
OC - Oceania 54
Continente sconosciuto - Info sul continente non disponibili 16
AN - Antartide 1
Totale 66.860
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.255
IT - Italia 5.391
RU - Federazione Russa 5.240
SG - Singapore 4.232
GB - Regno Unito 3.709
CN - Cina 3.674
IE - Irlanda 2.996
BR - Brasile 2.036
VN - Vietnam 1.787
SE - Svezia 1.381
FR - Francia 1.367
DE - Germania 1.364
HK - Hong Kong 1.287
FI - Finlandia 825
UA - Ucraina 807
KR - Corea 563
IN - India 528
ZA - Sudafrica 360
CA - Canada 296
ES - Italia 260
NL - Olanda 236
BD - Bangladesh 207
JP - Giappone 184
IQ - Iraq 165
PL - Polonia 150
TR - Turchia 146
MX - Messico 140
AR - Argentina 136
CZ - Repubblica Ceca 112
AT - Austria 100
CI - Costa d'Avorio 94
NG - Nigeria 89
PK - Pakistan 82
EC - Ecuador 70
ID - Indonesia 67
UZ - Uzbekistan 64
BE - Belgio 62
SA - Arabia Saudita 58
IR - Iran 54
VE - Venezuela 54
MA - Marocco 49
CO - Colombia 46
KE - Kenya 46
PH - Filippine 46
AU - Australia 43
CL - Cile 40
AE - Emirati Arabi Uniti 38
CH - Svizzera 38
LT - Lituania 35
JO - Giordania 34
PY - Paraguay 31
EG - Egitto 30
PT - Portogallo 30
AZ - Azerbaigian 29
PE - Perù 27
IL - Israele 25
RO - Romania 25
MY - Malesia 24
KZ - Kazakistan 23
DK - Danimarca 22
GR - Grecia 21
DZ - Algeria 20
JM - Giamaica 19
BG - Bulgaria 18
TN - Tunisia 18
AL - Albania 15
BO - Bolivia 15
ET - Etiopia 14
KG - Kirghizistan 14
LB - Libano 14
LV - Lettonia 14
NP - Nepal 14
UY - Uruguay 14
HU - Ungheria 13
OM - Oman 13
EE - Estonia 12
PA - Panama 12
SN - Senegal 11
CR - Costa Rica 10
CY - Cipro 10
PS - Palestinian Territory 10
BY - Bielorussia 9
EU - Europa 9
GE - Georgia 9
LK - Sri Lanka 9
MK - Macedonia 9
NO - Norvegia 9
DO - Repubblica Dominicana 8
QA - Qatar 8
RS - Serbia 8
TT - Trinidad e Tobago 8
LA - Repubblica Popolare Democratica del Laos 7
NZ - Nuova Zelanda 7
TH - Thailandia 7
TW - Taiwan 7
AM - Armenia 6
BB - Barbados 6
GY - Guiana 6
HN - Honduras 6
HR - Croazia 6
Totale 66.754
Salva come PNG Salva come JPEG
Città #
Dallas 4.509
Southend 3.025
Dublin 2.956
Singapore 2.552
Fairfield 2.070
Ashburn 1.985
Moscow 1.534
Chandler 1.426
Santa Clara 1.343
San Jose 1.198
Hong Kong 1.197
Beijing 916
Woodbridge 880
Siena 817
Hefei 788
Houston 774
Seattle 761
Wilmington 696
Cambridge 629
Jacksonville 587
Council Bluffs 576
Los Angeles 548
Milan 546
Seoul 529
Ho Chi Minh City 514
Helsinki 506
Munich 486
Princeton 473
New York 436
Hanoi 408
Ann Arbor 405
Lauterbourg 377
Florence 354
Lastra a Signa 349
The Dalles 340
Johannesburg 322
Rome 228
São Paulo 190
Dong Ket 184
Nanjing 178
Boardman 161
Buffalo 160
Shanghai 159
Chicago 158
San Diego 154
Orem 151
London 144
Tokyo 140
Dearborn 138
Bengaluru 137
San Mateo 127
Turku 123
Frankfurt am Main 120
Málaga 120
Warsaw 120
Redondo Beach 117
Fremont 100
Nuremberg 99
Da Nang 96
Lappeenranta 96
Abidjan 93
Chennai 90
Düsseldorf 82
Montreal 79
Abuja 77
Brooklyn 74
Nanchang 74
Haiphong 73
Stockholm 69
Portsmouth 67
Toronto 67
Brno 66
Rio de Janeiro 63
Denver 62
Phoenix 61
Atlanta 58
Washington 58
Baghdad 57
Manchester 57
Vienna 57
Guangzhou 55
Menlo Park 55
Amsterdam 54
Tashkent 54
Poplar 53
Shenyang 52
Ottawa 50
Naples 47
San Francisco 47
Columbus 46
Catania 44
Changsha 44
Boston 43
Brussels 43
Paris 43
Mexico City 42
Gavirate 41
Belo Horizonte 40
Hangzhou 40
Bologna 39
Totale 43.528
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.039
A first update on mapping the human genetic architecture of COVID-19 575
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 574
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 499
Genetic mechanisms of critical illness in COVID-19 410
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 388
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 387
Cytokine modulators in the treatment of sarcoidosis 380
An explainable model of host genetic interactions linked to COVID-19 severity 365
Antirheumatic agents in covid-19: is IL-6 the right target? 354
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 351
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 349
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 342
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 337
Pathogen-sugar interactions revealed by universal saturation transfer analysis 323
null 320
Peripheral biomarkers' panel for severe COVID-19 patients 316
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 311
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 308
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 305
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 292
POS0871 diagnostic accuracy og power doppler ultrasonography for the diagnosis of idiopathic inflammmatory myopathies 291
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 291
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 287
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 287
Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies 286
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 283
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways 282
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 279
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 278
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 273
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 272
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 272
Exhaled nitric oxide in interstitial lung diseases 271
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 271
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 268
Gorham-Stout disease management during pregnancy 264
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 261
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 261
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 260
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 260
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 258
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 256
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 254
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 253
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 252
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 250
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 249
Serial KL-6 measurements in COVID-19 patients 246
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 245
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 244
Prognostic bioindicators in severe COVID-19 patients 244
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 243
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 243
Omalizumab treatment in Samter's triad: case series and review of the literature 242
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 242
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 241
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 240
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 239
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 238
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 237
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 236
Serum amyloid A in patients with idiopathic pulmonary fibrosis 236
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 235
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 235
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 235
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 235
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 234
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 233
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 232
A functional proteomics approach to the comprehension of sarcoidosis 232
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 231
Chitotriosidase activity in patients with interstitial lung disesaes 227
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 225
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 224
Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer 224
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 224
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline 224
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 223
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 222
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 222
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 219
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 219
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 219
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 217
NK and NKT-like cells in granulomatous and fibrotic lung diseases 216
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 216
Analysis of carbonylated proteins in BAL of patients with diffuse lung diseases 215
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 215
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 215
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 214
Strategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review 214
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 213
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 213
Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases 213
SARS-CoV-2 in pleural fluid in a kidney transplant patient 213
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 212
The analysis of tryptase in serum of sarcoidosis patients 211
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 211
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 211
Totale 27.603
Salva come PNG Salva come JPEG
Categoria #
all - tutte 217.351
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 217.351
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.326 0 0 0 0 0 0 0 0 0 375 421 530
2021/20224.498 350 593 368 305 222 157 199 211 185 526 484 898
2022/20235.729 424 592 717 691 415 1.044 359 485 447 202 213 140
2023/20245.524 218 138 517 273 294 1.280 1.644 226 62 179 179 514
2024/202512.165 715 524 1.290 671 1.397 660 611 736 943 617 1.273 2.728
2025/202626.757 2.060 3.922 3.596 3.385 5.267 1.078 3.571 886 1.093 1.899 0 0
Totale 68.350